Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Locally Advanced Cervical Cancer Clinical Trial

Official title:

An Exploratory Clinical Study of Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06055738
• Other study ID #: TangduH-1
• Status: Recruiting
• Phase: Phase 2
• Start date: October 9, 2023
• Est. completion date: December 30, 2027

Study information

• Verified date: September 2023
• Source: Tang-Du Hospital
• Contact: Hongxi Zhao, PhD
• Phone: +8615094088350
• Email: zhaohx[@]fmmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, single arm, phase II clinical study to evaluate the efficacy and safety of Zimberelimab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer.

Description:

This study will enroll patients with IB3 and IIA2 locally advanced cervical cancer who received three cycles of neoadjuvant Zimberelimab combined with albumin-bound paclitaxel and cisplatin to evaluate the efficacy and safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 30, 2027
• Est. primary completion date: December 30, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntary participation in clinical research.

2. Age =18 years old, female.

3. Squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix confirmed by histology/cytology.

4. Previously untreated locally advancedcervical cancer (2018 FIGO stage IB3, IIA2) .

5. At least one measurable lesion was suitable for target lesion according to RECIST v1.1 .

6. Within 14 days before the first treatment, the major organ functions were basically normal.

7. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1;

8. Subjects agree to provide sufficient tumor tissue samples for PD-L1 expression detection;

9. If hepatitis B surface antigen (HBsAg) is positive and/or hepatitis B core antibody (HBcAb) is positive, hepatitis B virus DNA (HBV DNA) is detected, HBV DNA < 104 copies /ml or < 2000IU/mL can be enrolled. Or those who had received antiviral therapy for at least 4 weeks before the first dose of study drug and were willing to continue antiviral therapy during the study were eligible for enrollment. Those with HCV antibody positive should be excluded.

10. Subjects of childbearing age and their sexual partners agreed to consent to contraceptive use after signing an informed consent form, during treatment and for at least 6 months after the last dose of the study intervention.

Exclusion Criteria:

1. Patients with active autoimmune disease or a history of autoimmune disease.

2. Previous history of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation).

3. Use of immunosuppressive drugs within 14 days prior to treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (i.e., not more than 10 mg/ day of prednisolone or another corticosteroid at the physiological dose of the drug).

4. Previous treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, or anti-lymphocyte antigen 4 (CTLA-4) antibody.

5. Arterial or venous thromboembolic events within the previous 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein embolism or any other major thromboembolism, implantable venous access port or catheter-derived thrombosis, or superficial venous thrombosis. Except for patients with stable thrombus after conventional anticoagulant therapy, prophylactic use of low-dose low molecular weight heparin was allowed.

6. Previous history of gastrointestinal perforation, gastrointestinal fistula, genital fistula (such as vesicovaginal fistula, urethrovaginal fistula, vesicovaginal fistula, etc.); Patients were allowed if the perforation or fistula had been treated with diversion surgery, resection, or repair, and the disease was recovered or relieved as judged by the investigator.

7. Symptomatic congestive heart failure (New York Heart Association class II-IV) Arrhythmias with poorly controlled symptoms.

8. Active pulmonary tuberculosis, receiving anti-tuberculosis treatment.

9. Interstitial lung disease.

10. Severe infections that are active or poorly controlled clinically. Severe infection within 3 weeks before treatment, including but not limited to patients hospitalized for complications of infection, bacteremia, or severe pneumonia.

11. Central nervous system metastasis, leptomeningeal metastasis, spinal cord compression, or leptomeningeal disease.

12. Human immunodeficiency virus (HIV) infection, known syphilis infection.

13. Have received live vaccine within 4 weeks of the first use of the experimental drug, or plan to receive live vaccine during the study.

14. Known or suspected allergy to the trial drug or any drug related to the trial.

15. Pregnant or lactating women.

16. There were other conditions deemed by the investigator to be inappropriate for enrollment.

Related Conditions & MeSH terms

• Locally Advanced Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Zimberelimab
240mg,d1,iv,Q21D
• Albumin-bound Paclitaxel
260mg/m2,d1,iv,Q21D
• Cisplatin
75mg/m2,d1,iv,Q21D

Locations

Country	Name	City	State
China	Hongxi Zhao	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	Objective response rate based on RECIST v1.1, ORR was defined as the ratio of best complete response (CR) and partial response (PR) recorded from the start of treatment to the preoperative evaluation	3-4 months
Secondary	Complete pathological response (pCR)	Complete pathological response (pCR) was defined as the proportion of all surgical patients in whom no viable tumor cells were found in the resected specimen.	one year
Secondary	Major Pathological Response (MPR)	Major pathological response (MPR) was defined as the proportion of patients with =10% residual viable tumor cells in the resected specimen among all surgical patients.	one year
Secondary	R0 resection rate	R0 resection rate: defined as the proportion of patients undergoing surgical excision who had a negative margin of surgical specimens	one year
Secondary	Event-free survival (EFS)	Event-free survival (EFS) was defined as the time from the start of treatment to the first occurrence of any of the following events: disease progression beyond surgical treatment, local or distant recurrence, death from any cause, etc.	three years
Secondary	Overall survival (OS)	Overall survival (OS) : defined as the time between the initiation of treatment and death from any cause.	three years
Secondary	Adverse Events	Based on NCI-CTC AE v5.0	three years